B ecause the demand for donor hearts as a life-saving therapy has continued to exceed their supply, the United Network for Organ Sharing (UNOS) has periodically modified the allocation algorithm to improve outcomes among wait listed candidates in the United States (US). 1, 2 A change in allocation algorithm implemented on July 12, 2006 allowed broader regional sharing of available hearts to those in more immediate need (Status 1A and 1B candidates) prior to their allocation to local, less sick candidates. [3] [4] [5] A fundamental goal of the new algorithm is to decrease national wait list mortality among heart transplant (HT) candidates without a concurrent increase in post-transplant mortality. 2 The latter consideration arises from the observation that sicker patients, on average, are also at a higher risk of surgical mortality. 6, 7 Although early analyses after the change in allocation suggested that the trends in wait list outcomes were consistent with intended outcomes, 4,8 a regional analysis has questioned the merits of the new allocation algorithm. 5 
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We hypothesized that the risk of wait list mortality among HT candidates in the US has decreased since the implementation of the new allocation algorithm. The specific objectives of this study were (1) to compare overall and risk-adjusted wait list mortality before and after implementation of the new allocation algorithm, (2) to determine if wait list outcomes in subgroups of listed patients have been affected differently by the change in allocation algorithm, and (3) to compare overall (unadjusted) and risk-adjusted early post-transplant mortality before and after the change in allocation algorithm.
Methods

Study Population
We identified all patients Ն18 years of age in the Organ Procurement and Transplantation Network (OPTN) database who were listed for their first HT in the US between July 1, 2004 and June 30, 2009 . The OPTN database includes information at the time of listing for all wait Patients who were listed for a heart retransplantation or multiorgan transplantation were excluded. For analysis of wait list outcomes, all candidates were followed from the time of listing until death, HT, removal from the wait list, or the day of last observation on November 20, 2009 . Patients who received a HT were followed until hospital discharge, death, or the day of last observation.
Study Design and Definitions
The primary study hypothesis was that the risk of death on the wait list has decreased in the US since the implementation of the new allocation algorithm on July 12, 2006. We compared baseline characteristics and outcomes between patients listed for a primary HT during July 1, 2004 to July 11, 2006 (Era 1), and those listed during July 12, 2006 to June 30, 2009 (Era 2). The primary end point was a composite of death on the wait list or becoming too sick to transplant (removal from the wait list due to clinical deterioration). Patients who received a HT or those who were removed from the list due to recovery or other reasons were censored. Clinical variables were defined at the time of listing for analysis of wait list outcomes. Secondary end points included (1) post-transplant in-hospital mortality, (2) 1-year survival among those who received a HT and, (3) post-transplant length of stay in recipients who survived to hospital discharge. Post-transplant mortality was compared between groups defined by the date of listing (Era 1 versus Era 2, as defined above), rather than between groups defined by the date of HT (intention to treat principle). Post-transplant mortality was analyzed using clinical variables at the time of transplant.
Patient race/ethnicity was recorded as reported by the transplant center and analyzed as white, black, Hispanic, or Other. Renal function was analyzed as a categorical variable (plasma creatinine Ͼ1.5 mg/dL) and as estimated glomerular filtration rate using the Modification of Diet in Renal Disease formula. 9, 10 None of the subjects had any missing data for the variables of age, gender, race/ethnicity, cardiac diagnosis, blood type, hemodynamic support (intra-aortic balloon pump, inotrope support, ventilator, mechanical support), medical insurance (Medicaid), UNOS listing status, dialysis and the dates of listing, transplant, death, or removal from the wait list. For patients with missing data on other variables, we created indicator variables "variable not reported" for each such variable to allow these subjects to contribute their available risk factors in multivariable models.
Statistical Analysis
Summary data are presented as median (25th, 75th percentile) or number (percent). Baseline characteristics between patients in the 2 eras were compared using the 2 test for categorical and the Kruskal-Wallis test for continuous variables. Overall wait list mortality before and after the change in allocation algorithm was assessed using the Kaplan-Meier method and using competing outcomes analysis. 11, 12 A multivariable Cox proportional hazards model was developed using a forward selection procedure retaining variables significant at the 0.10 level based on a likelihood ratio test; all variables in Table 1 were considered. Interactions of patient risk factors with era were assessed to ascertain if the effect of allocation change on the primary end point has been significantly different in patient subgroups. A multivariable logistic regression model was developed to evaluate era effect for post-transplant in-hospital mortality among transplant recipients adjusted for baseline risk factors. A Cox regression model was used to evaluate era effect for 1-year survival. Post-transplant length of stay among those who survived to hospital discharge was compared during the 2 eras using an unpaired t test.
Data were analyzed using SAS statistical software version 9.1 (SAS Institute Inc.). All statistical tests were 2-sided, and a probability value of less than 0.05 was used to define statistical significance. The authors had full access to the data and take responsibility for its integrity. All authors have read and agreed to the manuscript as written.
Results
Study Population
During the 5-year study period, 11 864 patients Ն18 years of age were listed in the US for their primary HT and formed the study cohort. Of these, 4503 (38%) were listed before the Table 2) . Patients on a continuous-flow LVAD and those with an ICD were at lower risk of wait list mortality. Figure 3 demonstrates the risk of death on the wait list or becoming too sick to transplant in Era 2 compared with Era 1 in subgroups of patients controlling for risk factors identified in Table 2 . The improvement in wait list mortality was consistent across most subgroups, particularly those with Because the increased ventricular assist device (VAD) use in Era 2 may have contributed to the improved wait list outcomes, we performed a subgroup analysis on patients that were not VAD supported at either listing or transplant (nϭ9348). The competing outcomes and cumulative wait list mortality in Era 1 and Era 2 in non-VAD patients listed 1A/1B is illustrated in Figure 4 . In an adjusted model (adjusted for all variables in Table 2 ), non-VAD patients listed in Era 2 were at 23% lower risk of dying on the wait list or becoming too sick to transplant (HR 0.77, 95% CI 0.69, 0.87). Table 2 .
Subgroup Analysis
The median waiting time for HT was 63 days (interquartile range 19 -170 days) for patients listed during Era 1 and 55 days (interquartile range 17-146 days) for patients listed during Era 2 (PϽ0.0001). Although the median waiting times for HT in patients listed status 1A (20 versus 21 days) and those listed status 1B (48 versus 49 days) were similar in the 2 eras, a higher percentage of patients were transplanted as status 1A among those listed in Era 2 (37% in Era 1 versus 48% in Era 2, PϽ0.0001). The percentage of HT surgeries performed using hearts from local donors declined from 62% in Era 1 to 52% in Era 2 (PϽ0.001). As a result, the median distance between the recipient and the donor hospital increased in Era 2 (89 miles in Era 1 versus 125 miles in Era 2, PϽ0.001). Donor ischemic time for HT recipients was somewhat higher during Era 2 (3.2Ϯ1.0 hours versus 3.3Ϯ1.0 hours, Pϭ0.02). The proportion of patients whose level of support increased between listing and transplant (no mechanical support to any mechanical support or LVAD to bi-ventricular assist device/total artificial heart/ ECMO) was similar among patients listed during the 2 eras.
Among 7747 patients who received a HT and whose discharge status was known (3191 listed in Era 1, 4556 listed in Era 2), 7298 (94.2%) patients were discharged from the hospital by the last day of the study and 449 (5.8%) died prior to hospital discharge (Table S1 for clinical variables at transplant; see online-only supplement). Post-transplant inhospital mortality was 6.3% for HT recipients listed before and 5.4% for HT recipients after the allocation change. Table   3 lists risk factors for post-transplant in-hospital mortality in the study cohort. Listing after allocation change was not associated with a change in early post-transplant mortality (risk-adjusted odds ratio, 0.85 for Era 2 versus Era 1, 95% CI 0.69, 1.04, Pϭ0.11) or in 1 year survival (risk-adjusted HR 0.98 for Era 2 versus Era 1, 95% CI 0.85, 1.12, Pϭ0.73). Post-transplant length of stay (meanϮstandard deviation) among those who survived to discharge was similar during the 2 eras (20Ϯ25 days during Era 1 versus 19Ϯ18 days during Era 2, Pϭ0.09).
Discussion
In this study, we sought to assess whether the implementation of the new allocation algorithm in 2006 allowing broader regional sharing of donor hearts for sicker heart failure patients (those listed 1A and 1B) has been associated with a change in national wait list and early post-transplant mortality in the US. We found that the risk of dying on the HT wait list or becoming too sick to transplant has declined since the implementation of the new algorithm, as has the median waiting time among HT recipients. As expected, implementation of the new allocation algorithm has led to a higher percentage of HT surgeries being performed in patients listed status 1A. However, this redirection of donor hearts to sicker heart failure patients has not resulted in higher early posttransplant mortality. Although a higher VAD use in Era 2 probably has contributed to improved wait list outcomes, an important role of allocation change is suggested by (1) the improvement in wait list outcomes in patients not on VAD at either listing or at transplant, (2) unchanged wait list time in patients listed as status 1A, despite a higher percentage of patients listed and transplanted as status 1A, and (3) the decline in risk in the year following the allocation change. These findings suggest that the potential problems anticipated from change in allocation algorithm have not materialized, and the new allocation algorithm appears to be achieving its intended goal.
Since the early days of transplantation, UNOS has considered use/benefit and justice/fairness as the 2 fundamental ethical principles in allocating solid organs, giving equal weight to both. 13 Following the publication of the Final Rule by the Department of Health and Human services, 14 there were major changes in allocation of hearts, livers, and lungs, so that medical urgency became the predominant determinant of the new algorithms in the US. [15] [16] [17] [18] [19] Thus, patients listed for a HT have been considered in a new 3-tier system (versus a prior 2-tier system) of medical urgency since 1999. 1 It is important to note that allowing a broader sharing of donor hearts for 1A and 1B heart candidates is well within the scope of the First Rule (medical urgency first followed by firstcome first-served among those with equal medical urgency). It assumes, however, that sharing hearts with candidates located up to 500 miles of the donor hospital will lead to better overall wait list outcomes and will not result in decline in overall transplant benefit due to worse post-transplant outcomes or futile transplants. 14 The findings of our analysis support and expand on previous observations in the Scientific Registry of Transplant Recipients (SRTR) reports, which showed fewer deaths/ patient-years of wait list time early after the change in allocation algorithm. 4 Although the improvement in wait list outcomes was not confirmed in a subsequent regional analysis limited to Utah candidates, 5 regional heterogeneity in benefits of allocation change are to be expected, first because of the variations in recipient characteristics and donor pool in different regions, and second due to a relatively small number of subjects in each region. 20 Thus, an analytic approach similar to that employed in the current study for subjects of a single region may demonstrate lack of benefit due simply to a small sample size (type II error). The new algorithm does not explicitly consider the potential for worse prognosis in sicker patients. However, similar post-transplant survival in the 2 eras noted in the current analysis suggests that while subjects who received a HT in Era 2 were sicker, appropriate patient selection by transplant centers ensured that their risk profile for post-transplant outcomes was acceptable.
An examination of wait list mortality among patients listed for a HT in the US in SRTR reports (deaths/patient-years of wait list time) suggests a progressive decline in wait list mortality even before the new allocation algorithm was implemented. 4 This decline appeared to be particularly noticeable during the years 2001 to 2004, before appearing to plateau during 2004 to 2006, and may be explained by advances in HT candidate selection and in medical management of listed patients. Although the decline in wait list mortality observed in our study occurred coincident with the change in allocation, the relative contributions of the new allocation algorithm and the concurrent advances in care of heart failure patients to the decline in wait list mortality cannot be assessed because of the absence of a contra-factual cohort. An important role of the new allocation algorithm is suggested by a rather abrupt decline in overall and riskadjusted wait list mortality in the year following the allocation change, which then was maintained at that level in subsequent years.
The finding that the decrease in wait list mortality associated with the change in allocation algorithm was limited to white candidates was surprising, in particular because the interaction was observed after adjusting for all other risk factors (Figure 3) . A previous OPTN analysis for patients listed for a HT during 1990 to 2005 found white candidates to be at higher risk of death within 60 days of listing. 21 Potential explanations for lack of benefit from allocation change in minority candidates may include racial differences in the distributions of cardiac diagnoses, blood type, listing status, access to care, timing of presentation, and progression of heart failure. Further work is needed to determine if there are significant racial differences in wait list outcomes in the current era, and if so whether they are caused by biological differences among racial groups or represent racial disparities.
Because the results of wait list outcomes were predicted by a simulation that preceded the implementation of the new algorithm, they highlight the value of such simulations prior to changes in allocation algorithm. 2, 22 Future simulations could consider not only the effect of allowing longer distance between the donor and the recipient hospitals for those in immediate need of a transplant, but also other factors associated with worse wait list outcomes, such as the cardiac diagnosis. Almost half of all wait list deaths with the current allocation algorithm occur within 60 days of listing, suggesting the potential for such simulations to unearth further opportunities for improving wait list outcomes.
This study has a few limitations. First, being a retrospective analysis of a national database, the quality control of submitted data may not be as rigorous as in prospective, controlled trials. However, because these data are used by UNOS for real-time organ allocation and for subsequent evaluation of center performance, and are subject to periodic audit, reasonable safeguards to data quality may be expected. Second, patients who were waiting for a HT at the time of implementation of allocation change were affected by the new allocation and may have affected the results of the current analysis. Assuming a net benefit based on this analysis, however, this would bias the results of our analysis toward null and may suggest an underestimation of the magnitude of benefit associated with the change in allocation. Third, allocation change may not be the only explanation for improved wait list outcomes, despite our analysis adjusting for all available risk factors. Advances in heart failure management, particularly in management of patients on mechanical support, have occurred rapidly and may have contributed to the improved outcomes over and above that captured by multivariable analysis. However, the consistency of improvement in outcomes across subgroups, in particular those not on mechanical support at listing, suggests an important role of allocation change. Finally, these national outcomes may not be applicable to all US regions because individual regions represent nonrandom samples of the US population, with outcomes affected by differences in recipient characteristics and by local practice patterns and donation rates.
Conclusions
In conclusion, the risk of dying on the HT wait list or becoming too sick to transplant has declined in the US since the allocation algorithm allowing broader regional sharing was implemented in 2006. The shift in hearts to sicker HT candidates has not resulted in higher early post-transplant mortality.
